CMV

COMMUNIQUÉS West-GlobeNewswire

MAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy
13/08/2025
Cancer-fighting immunosuppressive agents shown to disrupt telomeres and suspend growth of cancer cells CHICAGO , Aug. 13, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), [...]
Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT - Advancing Breakthrough Therapy for Chronic Lower Back Pain
13/08/2025
PHOENIX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) , a clinical-stage biotechnology company focused on regenerative and immune cellular therapies, today announced that [...]
Corza Medical Launches Biomedical Textiles Innovation Lab to Accelerate OEM Product Development
13/08/2025
TAUNTON, U.K., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Corza Medical, a leading global manufacturer of surgical technologies and medical device components announced today the launch of its Biomedical Textiles Innovation Lab, [...]
LIO Launches Next-Generation Inpatient Mental Health Platform with Advanced Rounding, Monitoring, and Compliance Tools
13/08/2025
The platform’s capabilities will support frontline staff and facility leaders, and promote patient safety WILMINGTON, Del., Aug. 13, 2025 (GLOBE NEWSWIRE) -- LIO today announced the launch of its new all-in-one platform [...]
Scilex Holding Company (Nasdaq: SCLX) Announces Effectiveness of Registration Statement on Form S-4 for the Proposed Business Combination of Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, Inc., a Majority-Owned Subsidiary of Scilex
13/08/2025
Denali’s registration statement on Form S-4 declared effective by the Securities and Exchange Commission Extraordinary general meeting of Denali Capital Acquisition Corp. shareholders to approve the proposed business [...]
Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
13/08/2025
With the clearance of the U.S. IND, initiation of the U.S. clinical trial of AXN-2510/IMM2510 (“‘2510”) anticipated before the end of 2025 Updated ‘2510 monotherapy data in squamous-NSCLC to be presented at IASLC’s 2025 [...]
Neuronascent Announces Progress for Lead Candidate NNI-362: Publication of Phase 1a Clinical Trial Results and FDA Grants Waiver of Fee for Canine Cognitive Disorder 2025 Submissions
13/08/2025
BALTIMORE., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Neuronascent Inc., a privately-held neuron regeneration therapeutics company, today announced that the Phase 1a trial in aged human subjects of its NNI-362 therapy was [...]
Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania
13/08/2025
STAFFORD, Texas, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
Santhera Secures Agreement with GEN for the Distribution of AGAMREE® (Vamorolone) in Türkiye
13/08/2025
Pratteln, Switzerland , 13 August , 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Gen İlaç ve Sağlık Ürünleri San. ve Tic. A.Ş. (GEN) for the distribution and promotion [...]
Greywolf Therapeutics begins dosing of the first treatment to target the antigenic source of autoimmunity
13/08/2025
This is the first ever autoimmunity study to evaluate a potential functional cure that targets the antigenic source – the origin of autoimmune disease The Phase 1/2 study (up to 141 participants) will evaluate the [...]
Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering
13/08/2025
BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat [...]
Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates
12/08/2025
First patient treated with FT819 off-the-shelf CAR T-cell product candidate following fludarabine-free conditioning for severe lupus nephritis demonstrated durability of response with drug-free definition of remission [...]
Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
12/08/2025
– Positive ENLIGHTEN 2 Phase 3 results announced in June 2025 propel business activities in manufacturing, regulatory strategy and ENLIGHTEN clinical dataset analysis to advance path forward for LYR-210 for treatment of [...]
Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights
12/08/2025
Initial update for NKX019 in multiple autoimmune indications expected in second half of 2025 Cash balance of $334.0 million on June 30, 2025, including cash, cash equivalents and investments, expected to fund operations [...]
Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results
12/08/2025
– Company reports $12.7 million in revenue in Q2’25, consisting primarily of $4.5 million in YCANTH ® revenue, net, reflecting sequential growth of 32.5% over Q1’25 and $8.0 million in milestone revenue from Torii [...]
Editas Medicine Announces Second Quarter 2025 Results and Business Updates
12/08/2025
Company to select lead development candidate in September; on track to file IND by mid-2026 and achieve human proof-of-concept by year-end 2026 First IND/CTA accepted for CD19 HD Allo CAR T program as part of [...]
Erasca Reports Second Quarter 2025 Business Updates and Financial Results
12/08/2025
Efficient execution accelerated clinical entry of pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Phase 1 monotherapy data for RAS-targeting franchise expected in 2026 Robust balance sheet with cash, [...]
Compass Therapeutics Announces Proposed Public Offering
12/08/2025
BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat [...]
Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
12/08/2025
S econd quarter 2025 revenues were $15.0 million Emrosi™ net sales of $2.8 million generated in first full quarter on the market The Company joined the Russell 2000® and Russell 3000® Indexes in June 2025 Company to [...]

Pages